Adalimumab

Takayasu arteritis (TAK) is a rare chronic inflammatory disease affecting arteries, and there is no widely accepted effective treatment strategy. Researchers classify TAK patients into three severity levels: mild, moderate, and severe. This study focuses on severe TAK patients and compares two biological agents, tocilizumab and adalimumab, to find which treatment may provide better intervention outcomes in this group. The study randomly assigns severe TAK patients to receive either tocilizumab at a dose of 8mg/kg intravenously every four weeks or adalimumab at 40mg biweekly by injection for 24 weeks. Patients start with prednisone at 40mg daily, tapered gradually over months, and treatment adjustments are made if disease relapse occurs. After 24 weeks, if remission is not achieved, patients switch to the other biological agent for an additional 24 weeks. Participants are monitored throughout treatment and follow-up for disease remission using clinical and laboratory assessments. Researchers track disease relapse, vascular progression through angiographic exams, prednisone dose reduction, and quality of life changes using questionnaires over a total of 48 weeks. The primary outcome is disease remission at 24 weeks. Safety and disease activity are closely observed during the study.

Researchers are evaluating adalimumab for patients with acute Vogt-Koyanagi-Harada (VKH) disease to test if it provides clinical benefits. This observational study divides participants into two groups: one receiving adalimumab therapy and the other receiving traditional treatment with glucocorticoids alone or combined with immunosuppressants. The study follows ethical guidelines and informed consent was obtained from all patients. In the adalimumab group, patients receive an initial subcutaneous dose of 80 mg, then 40 mg every two weeks. Therapy continues for six months after ocular inflammation subsides, followed by tapered injections until withdrawal after 40 days. The traditional therapy group follows glucocorticoid treatment starting at 1 mg/kg/day, gradually stopped over 90 to 180 days. The study lasts up to one year to track treatment outcomes and side effects. Participants undergo regular assessments including best corrected visual acuity (BCVA), anterior chamber and vitreous inflammation, optical coherence tomography (OCT), and corticosteroid dose changes. Researchers monitor anti-inflammatory and immunosuppressive effects of adalimumab, visual acuity changes, and recurrence rate at 24 weeks. Prednisone exposure is also tracked over 12 months to evaluate treatment impact and safety throughout the study period.